Efficacy and Safety of Acotiamide for the Treatment of Functional Dyspepsia: Systematic Review and Meta-Analysis

Table 3

Pooled RR of acotiamide versus placebo for nonresponders by Mantel-Haenszel fixed-effect model.

Groups or subgroups	Number of trials [reference]	Number of patients	RR; 95% CI	value	Test of heterogeneity
					value
Overall symptoms	2 [16]	768	0.95; 0.73–1.24	0.710	0.510	0%
50 mg, tid	1 [16]	227	1.46; 0.78–2.73	0.230	NA	NA
100 mg, tid	2 [16]	431	0.83; 0.55–1.26	0.380	0.420	0%
300 mg, tid	2 [16]	441	0.90; 0.60–1.34	0.590	0.590	0%
PDS	2 [16]	396	0.71; 0.50–1.02	0.060	0.300	18%
50 mg, tid	1 [16]	151	1.22; 0.64–2.34	0.540	NA	NA
100 mg, tid	2 [16]	206	0.51; 0.26–0.99	0.050	0.370	0%
300 mg, tid	2 [16]	218	0.61; 0.34–1.10	0.100	0.560	0%
EPS^a	2 [16]	320	1.76; 0.90–3.45	0.100	0.190	35%
50 mg, tid	1 [16]	73	3.89; 0.46–33.17	0.210	NA	NA
100 mg, tid	2 [16]	184	1.91; 0.48–7.57	0.360	0.170	47%
300 mg, tid	2 [16]	192	2.31; 0.34–15.74	0.390	0.070	70%

^aMantel-Haenszel random-effects model.
CI, confidential interval; FD, functional dyspepsia; NA, not applicable; RR, risk ratio; and tid, three times daily.